Michael Wang, MD

Michael Wang, MD, discusses where unmet needs still exist for patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses where future research efforts for pirtobrutinib will be focused for patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the background of the phase 3 BRUIN MCL-321 trial and how positive results may shape the future of the mantle cell lymphoma space.

Michael Wang, MD, discusses what led to the start of the phase 3 BRUIN MCL-321 trial for patients with mantle cell lymphoma.

Michael Wang, MD, gives a brief overview of the safety and efficacy findings of a phase 1b study evaluating acalabrutinib plus venetoclax and rituximab in patients with mantle cell lymphoma.

Study results may indicate for a potential alternative treatment option to address the unmet needs for elderly patients with newly diagnosed mantle cell lymphoma, according to Michael Wang, MD.

Michael Wang, MD, discusses the study design of the ongoing, multicenter, open-label study examining an acalabrutinib triplet in MCL.

Michael Wang, MD, discusses the growing awareness of chimeric antigen receptor T-cell therapy among community oncologists and patients with mantle cell lymphoma.

Michael Wang, MD, discusses current and upcoming treatments being investigated for patients with mantle cell lymphoma.

Michael Wang, MD, discusses potential upcoming treatment options for patients with mantle cell lymphoma, including targeted therapies and chimeric antigen receptor T cells.

Michael Wang, MD, discusses the role of BTK inhibitors as treatment of patients with mantle cell lymphoma ahead of his presentation at the 2020 SOHO Annual Meeting.

Michael Wang, MD, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial.

Michael Wang, MD, discusses the approaches physicians can use when treating their patients with mantle cell lymphoma who have become resistant to cellular therapies, such as CAR T-cell therapy.

Michael Wang, MD, discusses the potential role for the next-generation Bruton's tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.